Storage Stability
SDF-1 (CXCL12) is a constitutively expressed CXC chemokine produced by bone marrow stromal cells and many other tissues. It is the primary chemotactic factor for CXCR4-expressing hematopoietic stem cells, and the SDF-1/CXCR4 axis governs stem cell homing, retention, and mobilization in the bone marrow. Disruption of this axis by plerixafor (AMD3100) is FDA-approved for hematopoietic stem cell mobilization.
Mechanism of Action
- CXCR4 activation drives Gi-mediated inhibition of cAMP, activation of PI3K/Akt, ERK1/2, and PLC; net effect is cell survival and directed migration toward SDF-1 gradients
- Bone marrow SDF-1 gradient retains CXCR4+ HSCs in BM niche; G-CSF and plerixafor disrupt this gradient to mobilize HSCs into circulation
- CXCR7/ACKR3 acts as a scavenger receptor: internalizes SDF-1 without classical signaling; shapes tissue SDF-1 gradients
- Tumor chemotaxis: CXCR4+ tumor cells follow SDF-1 gradients to metastatic sites (lymph node, bone, lung, liver)
- Angiogenesis: SDF-1 recruits CXCR4+ endothelial progenitor cells (EPCs) to ischemic tissue, promoting new vessel formation
Research Findings
- CXCR4 is the co-receptor for HIV-1 entry (X4 tropic strains); SDF-1 can block HIV infection by competing for CXCR4
- Plerixafor (AMD3100, CXCR4 antagonist) FDA-approved 2008: combined with G-CSF, mobilizes HSCs for autologous stem cell transplant in NHL and MM
- SDF-1 overexpression in ischemic heart improved EPC recruitment and cardiac function in mouse MI models
- CXCR4/SDF-1 axis is the dominant pathway for HSC homing to bone marrow after transplant; CXCR4 antagonism during mobilization and CXCR4 agonism for engraftment enhancement are both therapeutic strategies
- AMD11070 and LY2510924 (CXCR4 antagonists): in clinical trials for AML, CXCR4-overexpressing cancers, and HIV
Research Protocols
- HSC mobilization research: 100 mcg/kg SDF-1 SC or IV in mice to assess EPC/HSC tissue homing (opposite of plerixafor)
- Chemotaxis assay: 100-300 ng/mL SDF-1 as chemoattractant in Boyden chamber with CXCR4+ tumor or stem cells
- Cardiac: 1-10 mcg intramyocardial SDF-1 injection after MI in rodents; measure infarct size and EPC recruitment at 4 weeks
- CXCR4 binding: 125I-SDF-1 displacement; Kd ~0.5-3 nM for CXCR4; Ki of plerixafor ~2-10 nM
Interactions
- CXCR4: primary signaling receptor; plerixafor (AMD3100) is FDA-approved antagonist for stem cell mobilization
- G-CSF: synergistic with CXCR4 blockade for HSC mobilization; G-CSF downregulates BM SDF-1, plerixafor blocks residual CXCR4 retention
- CXCR7/ACKR3: scavenging receptor that clears SDF-1; CXCR7 antagonists may amplify SDF-1 availability in tissues
Safety Profile
SDF-1 itself is a research/clinical research reagent. Plerixafor (CXCR4 antagonist) FDA-approved with manageable side effects (nausea, diarrhea, injection site reactions, orthostatic hypotension). SDF-1 agonism risk: potential for CXCR4+ tumor recruitment to preferred niches.
Legal & Regulatory
SDF-1 is a research reagent. Plerixafor (Mozobil, CXCR4 antagonist) FDA-approved 2008 for HSC mobilization.
Ready to dose SDF-1 (CXCL12)?
Get the exact syringe draw
You have read the research. Now run the math. Pick your vial size and BAC water volume, get IU draw in seconds.
Open the Calculator →
More in Tissue Repair
View all →